Precision BioSciences获FDA孤儿药资格认定用于治疗杜氏肌营养不良症

英为财情

2025/07/18

Investing.com -- Precision BioSciences (NASDAQ:DTIL)已获得美国食品药品监督管理局(FDA)对其靶向杜氏肌营养不良症的核酸酶治疗的孤儿药资格认定。该认定授予了该公司的腺相关病毒9型递送的DMD19-20L.431和DMD35-36L.457核酸酶，这些核酸酶正在开发用于治疗杜氏肌营养不良症。孤儿药资格认定授予用于治疗、诊断或预防在美国影响不足...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552343604"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552343604\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552343604?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-18 00:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552343604","market":"us","top_or_hot":-1,"title":"Precision BioSciences获FDA孤儿药资格认定用于治疗杜氏肌营养不良症","media":"英为财情","content":"<div>\n<p>Investing.com -- Precision BioSciences (NASDAQ:DTIL)已获得美国食品药品监督管理局(FDA)对其靶向杜氏肌营养不良症的核酸酶治疗的孤儿药资格认定。\n该认定授予了该公司的腺相关病毒9型递送的DMD19-20L.431和DMD35-36L.457核酸酶，这些核酸酶正在开发用于治疗杜氏肌营养不良症。\n孤儿药资格认定授予用于治疗、诊断或预防在美国影响不足...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2890912\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precision BioSciences获FDA孤儿药资格认定用于治疗杜氏肌营养不良症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecision BioSciences获FDA孤儿药资格认定用于治疗杜氏肌营养不良症\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-18 00:11 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2890912><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- Precision BioSciences (NASDAQ:DTIL)已获得美国食品药品监督管理局(FDA)对其靶向杜氏肌营养不良症的核酸酶治疗的孤儿药资格认定。\n该认定授予了该公司的腺相关病毒9型递送的DMD19-20L.431和DMD35-36L.457核酸酶，这些核酸酶正在开发用于治疗杜氏肌营养不良症。\n孤儿药资格认定授予用于治疗、诊断或预防在美国影响不足...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2890912\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DTIL","symbol_name":"Precision Biosciences Inc","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2890912","article_id":"2552343604","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2890912","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552343604","pubTimestamp":1752768660,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- Precision BioSciences 已获得美国食品药品监督管理局对其靶向杜氏肌营养不良症的核酸酶治疗的孤儿药资格认定。该认定授予了该公司的腺相关病毒9型递送的DMD19-20L.431和DMD35-36L.457核酸酶，这些核酸酶正在开发用于治疗杜氏肌营养不良症。杜氏肌营养不良症是一种罕见的遗传性疾病，特征为肌肉逐渐退化和无力，这是由于一种称为肌营养不良蛋白的蛋白质发生改变，该蛋白质有助于保持肌肉细胞的完整性。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"DTIL":"Precision Biosciences Inc","BK4139":"生物科技"},"translate_title":"Precision BioSciences receives FDA orphan drug designation for the treatment of Duchenne muscular dystrophy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTIL":1},"content_text":"Investing.com -- Precision BioSciences (NASDAQ:DTIL)已获得美国食品药品监督管理局(FDA)对其靶向杜氏肌营养不良症的核酸酶治疗的孤儿药资格认定。\n该认定授予了该公司的腺相关病毒9型递送的DMD19-20L.431和DMD35-36L.457核酸酶，这些核酸酶正在开发用于治疗杜氏肌营养不良症。\n孤儿药资格认定授予用于治疗、诊断或预防在美国影响不足20万人的罕见疾病的药物和生物制品。这一地位为药物开发商提供了某些优势，包括合格临床试验的税收抵免和潜在的市场独占权。\n杜氏肌营养不良症是一种罕见的遗传性疾病，特征为肌肉逐渐退化和无力，这是由于一种称为肌营养不良蛋白的蛋白质发生改变，该蛋白质有助于保持肌肉细胞的完整性。\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}